Japan-based pharmaceutical giant Takeda Pharmaceutical has announced a partnership deal with Swiss biotech firm AC Immune to invest up to $2.2 billion in the development of a potential Alzheimer’s disease treatment.
According to a statement released by Takeda, the collaboration centres on an exclusive global option and license agreement focusing on AC Immune’s active immunotherapies that target harmful amyloid beta proteins, including their ACI-24.060 candidate for Alzheimer’s disease treatment.
Under the terms of the agreement, AC Immune will receive an initial payment of $100 million, with the possibility of earning up to an additional $2.1 billion in option fees and payments linked to various development, commercialization, and sales milestones throughout the duration of the agreement.
Furthermore, AC Immune is set to receive tiered double-digit royalties on global net sales of any successful products developed through this collaboration.
Alzheimer’s disease is a progressive neurological disorder that leads to memory loss and cognitive decline.
It is characterized by the buildup of amyloid beta plaques in the brain, which are believed to play a critical role in the disease’s progression.
The partnership between Takeda and AC Immune represents a significant investment in the fight against Alzheimer’s, focusing on novel immunotherapy approaches that target these toxic proteins.
This agreement highlights the ongoing efforts and collaborations in the pharmaceutical industry to develop effective treatments for neurodegenerative diseases, which remain a major challenge in healthcare due to their complex nature and the aging global population.
